Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMANDEEP SALHOTRA

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1659539021
CMS profile
211324
Location
DUARTE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$94,625.99

80 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMANDEEP SALHOTRA

NPI 1659539021 · CMS profile ID 211324

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology

DUARTE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659539021?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMANDEEP SALHOTRA, NPI 1659539021, CMS profile ID 211324. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659539021?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). AMANDEEP SALHOTRA, NPI 1659539021, CMS profile ID 211324. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659539021?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
AMANDEEP SALHOTRA, NPI 1659539021, CMS profile ID 211324, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–80 of 80 matching records. This page contains 30 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1659539021?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

80 matching records · $94,625.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 80 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–80 of 80.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Incyte Corporation $2,740.0006/11/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226161189 CMS
Incyte Corporation $1,087.7006/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226006629 CMS
Incyte Corporation $106.0306/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226170769 CMS
GENZYME CORPORATION $250.0006/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233690529 CMS
GENZYME CORPORATION $329.5106/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233690535 CMS
GENZYME CORPORATION $236.0506/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233690537 CMS
Incyte Corporation $140.0006/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226006625 CMS
Incyte Corporation $33.2505/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225976700 CMS
Incyte Corporation $18.4705/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225976708 CMS
Incyte Corporation $102.5905/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225976710 CMS
Incyte Corporation $480.0005/20/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1225976712 CMS
Incyte Corporation $5,480.0005/20/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226005175 CMS
Incyte Corporation $75.2205/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225976696 CMS
Incyte Corporation $25.2305/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225976702 CMS
Incyte Corporation $226.9605/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225976704 CMS
Incyte Corporation $398.9905/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225976714 CMS
SANOFI-AVENTIS U.S. LLC $81.4605/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233690463 CMS
Incyte Corporation $183.7805/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226005007 CMS
Incyte Corporation $47.2505/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226005167 CMS
Incyte Corporation $457.9805/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226005169 CMS
Incyte Corporation $227.3805/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226005171 CMS
Incyte Corporation $216.6005/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226005173 CMS
Incyte Corporation $10.4405/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226005177 CMS
Incyte Corporation $135.5705/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226043722 CMS
Incyte Corporation $685.0003/26/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226005275 CMS
Incyte Corporation $342.5003/26/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226005277 CMS
SOBI, INC $131.1002/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240266199 CMS
SOBI, INC $20.6002/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240266204 CMS
SOBI, INC $23.0702/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240266208 CMS
Daiichi Sankyo Inc. $13.5602/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197092753 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,766.69 14
PY2020 $186.79 7
PY2021 $5,274.03 11
PY2022 $5,838.43 8
PY2023 $62,989.56 64
PY2024 $39,598.37 30
PY2025 $94,625.99 80

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,093,075.96 183
PY2024 Principal investigator $259,723.17 13
PY2023 Principal investigator $64,349.09 8
PY2022 Principal investigator $185,248.32 7
PY2021 Principal investigator $176,389.07 7
PY2020 Principal investigator $196,364.52 7
PY2019 Principal investigator $91,267.60 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

183 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,702.00 12/24/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A STUDY TO EVALUATE VIMSELTINIB IN ADULTS WITH ACTIVE CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) No dispute reported 06/30/2026 1235967620
Principal investigator 1 Incyte Corporation $1,192.00 12/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470763
Principal investigator 1 Incyte Corporation $143.00 12/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470767
Principal investigator 1 Incyte Corporation $6,000.00 12/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470774
Principal investigator 1 Incyte Corporation $4,164.00 12/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470785
Principal investigator 1 Incyte Corporation $4,164.00 12/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470789
Principal investigator 1 Incyte Corporation $32,632.80 12/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470814
Principal investigator 1 Incyte Corporation $4,155.00 12/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470840
Principal investigator 1 Incyte Corporation $7,697.00 12/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470856
Principal investigator 1 Incyte Corporation $574.00 12/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470859
Principal investigator 1 Incyte Corporation $5,915.00 12/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470900
Principal investigator 1 Incyte Corporation $5,370.00 12/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470908
Principal investigator 1 Incyte Corporation $2,925.00 12/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470943
Principal investigator 1 Incyte Corporation $5,753.00 12/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470952
Principal investigator 1 Incyte Corporation $2,436.00 12/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470960
Principal investigator 1 Incyte Corporation $3,016.00 12/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470971
Principal investigator 1 Incyte Corporation $2,825.00 12/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470975
Principal investigator 1 Incyte Corporation $2,825.00 12/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470979
Principal investigator 1 Deciphera Pharmaceuticals Inc. $10,510.00 11/21/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A STUDY TO EVALUATE VIMSELTINIB IN ADULTS WITH ACTIVE CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) No dispute reported 06/30/2026 1235967616
Principal investigator 1 Deciphera Pharmaceuticals Inc. $7,058.00 11/19/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A STUDY TO EVALUATE VIMSELTINIB IN ADULTS WITH ACTIVE CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) No dispute reported 06/30/2026 1235967612
Principal investigator 1 Incyte Corporation $3,738.90 11/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470771
Principal investigator 1 Incyte Corporation $3,381.00 11/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470781
Principal investigator 1 Incyte Corporation $722.00 11/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470803
Principal investigator 1 Incyte Corporation $4,705.00 11/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470836
Principal investigator 1 Incyte Corporation $3,016.00 11/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470844
Principal investigator 1 Incyte Corporation $3,016.00 11/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470848
Principal investigator 1 Incyte Corporation $54.00 11/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470872
Principal investigator 1 Incyte Corporation $937.30 11/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470875
Principal investigator 1 Incyte Corporation $2,825.00 11/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470888
Principal investigator 1 Incyte Corporation $2,825.00 11/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470891
Principal investigator 1 Incyte Corporation $2,825.00 11/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470896
Principal investigator 1 Incyte Corporation $4,315.00 11/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470904
Principal investigator 1 Incyte Corporation $3,712.00 11/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470939
Principal investigator 1 Incyte Corporation $3,332.00 11/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470964
Principal investigator 1 Incyte Corporation $3,332.00 11/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470968
Principal investigator 1 Incyte Corporation $4,164.00 11/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240471002
Principal investigator 1 Incyte Corporation $4,164.00 11/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240471005
Principal investigator 1 Incyte Corporation $4,164.00 11/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240471010
Principal investigator 1 Incyte Corporation $4,164.00 11/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240471013
Principal investigator 1 Incyte Corporation $4,164.00 11/17/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240471017
Principal investigator 1 Incyte Corporation $57.59 11/10/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470765
Principal investigator 1 Incyte Corporation $186.39 11/10/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470777
Principal investigator 1 Incyte Corporation $49.36 11/10/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470793
Principal investigator 1 Incyte Corporation $49.36 11/10/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470798
Principal investigator 1 Incyte Corporation $19.14 11/10/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470824
Principal investigator 1 Incyte Corporation $19.14 11/10/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470828
Principal investigator 1 Incyte Corporation $606.40 11/10/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470832
Principal investigator 1 Incyte Corporation $297.70 11/10/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470852
Principal investigator 1 Incyte Corporation $202.74 11/10/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470911
Principal investigator 1 Incyte Corporation $177.98 11/10/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470915
Principal investigator 1 Incyte Corporation $117.56 11/10/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470920
Principal investigator 1 Incyte Corporation $117.56 11/10/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470923
Principal investigator 1 Incyte Corporation $161.80 11/10/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470926
Principal investigator 1 Incyte Corporation $575.90 11/10/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470930
Principal investigator 1 Incyte Corporation $274.80 11/10/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470935
Principal investigator 1 Incyte Corporation $60.64 11/10/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470948
Principal investigator 1 Deciphera Pharmaceuticals Inc. $435.00 11/09/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A STUDY TO EVALUATE VIMSELTINIB IN ADULTS WITH ACTIVE CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) No dispute reported 06/30/2026 1235967608
Principal investigator 1 National Marrow Donor Program $256.00 11/07/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events (MEASURE) No dispute reported 06/30/2026 1249326103
Principal investigator 1 Deciphera Pharmaceuticals Inc. $9,404.00 10/24/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A STUDY TO EVALUATE VIMSELTINIB IN ADULTS WITH ACTIVE CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) No dispute reported 06/30/2026 1235967604
Principal investigator 1 Incyte Corporation $14.79 10/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470769
Principal investigator 1 Incyte Corporation $14.21 10/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470807
Principal investigator 1 Incyte Corporation $9.28 10/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470810
Principal investigator 1 Incyte Corporation $20.88 10/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470819
Principal investigator 1 Incyte Corporation $209.28 10/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470863
Principal investigator 1 Incyte Corporation $60.96 10/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470868
Principal investigator 1 Incyte Corporation $83.93 10/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470879
Principal investigator 1 Incyte Corporation $34.41 10/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470884
Principal investigator 1 Incyte Corporation $128.62 10/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470956
Principal investigator 1 Incyte Corporation $72.54 10/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470983
Principal investigator 1 Incyte Corporation $137.34 10/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470987
Principal investigator 1 Incyte Corporation $7.25 10/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470993
Principal investigator 1 Incyte Corporation $74.12 10/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470997
Principal investigator 1 Syndax Pharmaceuticals, Inc. $661.98 10/08/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
AGAVE-201, A PHASE 2, OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF AXATILIMAB AT 3 DIFFERENT DOSES IN PATIENTS WITH RECURRENT OR REFRACTORY ACTIVE CHRONIC GRAFT VERSUS HOST DISEASE WHO HAVE RECEIVED AT LEAST 2 LINES OF SYSTEMIC THERAPY No dispute reported 06/30/2026 1249049470
Principal investigator 1 Deciphera Pharmaceuticals Inc. $580.00 10/03/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A STUDY TO EVALUATE VIMSELTINIB IN ADULTS WITH ACTIVE CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) No dispute reported 06/30/2026 1235967600
Principal investigator 1 Incyte Corporation $2,031.20 09/30/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470721
Principal investigator 1 Incyte Corporation $4,164.00 09/30/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470723
Principal investigator 1 Incyte Corporation $3,016.00 09/30/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470725
Principal investigator 1 Incyte Corporation $3,015.00 09/30/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470755
Principal investigator 1 Incyte Corporation $4,164.00 09/30/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470757
Principal investigator 1 Incyte Corporation $4,164.00 09/30/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470759
Principal investigator 1 Rigel Pharmaceuticals, Inc. $42,831.62 09/19/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
Pilot Phase 1 Trial of Olutasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplantation in Patients Carrying IDH1 Mutation with AML, MDS, or CMML Disease No dispute reported 06/30/2026 1249030081
Principal investigator 1 Deciphera Pharmaceuticals Inc. $435.00 09/14/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A STUDY TO EVALUATE VIMSELTINIB IN ADULTS WITH ACTIVE CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) No dispute reported 06/30/2026 1235967596
Principal investigator 1 SANOFI US SERVICES INC. $9,081.00 09/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of Belumosudil in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease (cGVHD) No dispute reported 06/30/2026 1226084552
Principal investigator 1 Deciphera Pharmaceuticals Inc. $11,820.00 08/22/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A STUDY TO EVALUATE VIMSELTINIB IN ADULTS WITH ACTIVE CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) No dispute reported 06/30/2026 1235967592
Principal investigator 1 Incyte Corporation $74.04 08/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470715
Principal investigator 1 Incyte Corporation $48.54 08/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470717
Principal investigator 1 Incyte Corporation $125.95 08/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470719
Principal investigator 1 Incyte Corporation $875.30 08/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470741
Principal investigator 1 Incyte Corporation $3,015.00 08/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470743
Principal investigator 1 Incyte Corporation $3,016.00 08/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470745
Principal investigator 1 Incyte Corporation $4,315.00 08/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470747
Principal investigator 1 Incyte Corporation $2,420.00 08/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470749
Principal investigator 1 Incyte Corporation $5,625.00 08/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470753
Principal investigator 1 National Marrow Donor Program $256.00 08/01/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events (MEASURE) No dispute reported 06/30/2026 1249326105
Principal investigator 1 Deciphera Pharmaceuticals Inc. $290.00 07/21/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A STUDY TO EVALUATE VIMSELTINIB IN ADULTS WITH ACTIVE CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) No dispute reported 06/30/2026 1235967589
Principal investigator 1 SANOFI US SERVICES INC. $8,202.00 07/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of Belumosudil in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease (cGVHD) No dispute reported 06/30/2026 1226084537
Principal investigator 1 SANOFI US SERVICES INC. $217,403.00 07/14/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of Belumosudil in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease (cGVHD) No dispute reported 06/30/2026 1226084532
Principal investigator 1 Deciphera Pharmaceuticals Inc. $25,753.00 07/11/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A STUDY TO EVALUATE VIMSELTINIB IN ADULTS WITH ACTIVE CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) No dispute reported 06/30/2026 1235967585
Principal investigator 1 Incyte Corporation $9,318.00 07/09/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470727
Principal investigator 1 Incyte Corporation $3,381.00 07/09/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470729
Principal investigator 1 Incyte Corporation $797.30 07/09/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470731
Principal investigator 1 Incyte Corporation $2,420.00 07/09/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470733
Principal investigator 1 Incyte Corporation $4,164.00 07/09/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470735
Principal investigator 1 Incyte Corporation $3,015.00 07/09/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470737
Principal investigator 1 Incyte Corporation $3,381.00 07/09/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470739
Principal investigator 1 Incyte Corporation $5,625.00 07/09/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470751
Principal investigator 1 Incyte Corporation $2,420.00 07/09/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470761
Principal investigator 1 Incyte Corporation $1,281.50 06/11/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470677
Principal investigator 1 Incyte Corporation $9,318.00 06/11/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470679
Principal investigator 1 Incyte Corporation $2,825.00 06/11/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470681
Principal investigator 1 Incyte Corporation $4,164.00 06/11/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470683
Principal investigator 1 Incyte Corporation $2,420.00 06/11/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470685
Principal investigator 1 Incyte Corporation $4,315.00 06/11/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470687
Principal investigator 1 Incyte Corporation $2,825.00 06/11/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470689
Principal investigator 1 Incyte Corporation $3,015.00 06/11/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470691
Principal investigator 1 SANOFI US SERVICES INC. $809.03 06/09/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of Belumosudil in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease (cGVHD) No dispute reported 06/30/2026 1226084514
Principal investigator 1 SANOFI US SERVICES INC. $30,000.00 06/09/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of Belumosudil in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease (cGVHD) No dispute reported 06/30/2026 1226084518
Principal investigator 1 Deciphera Pharmaceuticals Inc. $435.00 05/20/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A STUDY TO EVALUATE VIMSELTINIB IN ADULTS WITH ACTIVE CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) No dispute reported 06/30/2026 1235967581
Principal investigator 1 Deciphera Pharmaceuticals Inc. $38,610.00 05/14/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A STUDY TO EVALUATE VIMSELTINIB IN ADULTS WITH ACTIVE CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) No dispute reported 06/30/2026 1235967577
Principal investigator 1 Incyte Corporation $2,366.00 05/12/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470671
Principal investigator 1 Incyte Corporation $4,164.00 05/12/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470673
Principal investigator 1 Incyte Corporation $4,452.70 05/12/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470675
Principal investigator 1 National Marrow Donor Program $1,969.00 05/09/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events (MEASURE) No dispute reported 06/30/2026 1249325163
Principal investigator 1 Incyte Corporation $146.95 05/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470625
Principal investigator 1 Incyte Corporation $74.04 05/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470627
Principal investigator 1 Incyte Corporation $286.25 05/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470629
Principal investigator 1 Incyte Corporation $145.62 05/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470631
Principal investigator 1 Deciphera Pharmaceuticals Inc. $435.00 04/22/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A STUDY TO EVALUATE VIMSELTINIB IN ADULTS WITH ACTIVE CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) No dispute reported 06/30/2026 1235967573
Principal investigator 1 Incyte Corporation $4,164.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470633
Principal investigator 1 Incyte Corporation $3,016.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470635
Principal investigator 1 Incyte Corporation $4,315.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470637
Principal investigator 1 Incyte Corporation $4,164.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470639
Principal investigator 1 Incyte Corporation $4,164.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470641
Principal investigator 1 Incyte Corporation $3,381.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470643
Principal investigator 1 Incyte Corporation $2,420.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470645
Principal investigator 1 Incyte Corporation $2,420.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470647
Principal investigator 1 Incyte Corporation $3,712.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470649
Principal investigator 1 Incyte Corporation $9,318.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470651
Principal investigator 1 Incyte Corporation $5,625.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470653
Principal investigator 1 Incyte Corporation $3,381.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470655
Principal investigator 1 Incyte Corporation $1,110.80 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470657
Principal investigator 1 Incyte Corporation $4,315.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470659
Principal investigator 1 Incyte Corporation $5,625.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470661
Principal investigator 1 Incyte Corporation $4,633.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470663
Principal investigator 1 Incyte Corporation $9,318.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470665
Principal investigator 1 Incyte Corporation $4,164.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470667
Principal investigator 1 Incyte Corporation $2,521.20 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470669
Principal investigator 1 Incyte Corporation $3,016.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470693
Principal investigator 1 Incyte Corporation $3,016.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470695
Principal investigator 1 Incyte Corporation $3,016.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470697
Principal investigator 1 Incyte Corporation $3,381.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470699
Principal investigator 1 Incyte Corporation $2,420.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470701
Principal investigator 1 Incyte Corporation $2,420.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470703
Principal investigator 1 Incyte Corporation $4,315.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470705
Principal investigator 1 Incyte Corporation $2,825.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470707
Principal investigator 1 Incyte Corporation $2,825.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470709
Principal investigator 1 Incyte Corporation $2,825.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470711
Principal investigator 1 Incyte Corporation $2,825.00 04/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470713
Principal investigator 1 Deciphera Pharmaceuticals Inc. $10,846.00 04/09/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A STUDY TO EVALUATE VIMSELTINIB IN ADULTS WITH ACTIVE CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) No dispute reported 06/30/2026 1235967565
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,598.00 04/09/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A STUDY TO EVALUATE VIMSELTINIB IN ADULTS WITH ACTIVE CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) No dispute reported 06/30/2026 1235967569
Principal investigator 1 Deciphera Pharmaceuticals Inc. $580.00 03/27/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A STUDY TO EVALUATE VIMSELTINIB IN ADULTS WITH ACTIVE CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) No dispute reported 06/30/2026 1235967562
Principal investigator 1 Deciphera Pharmaceuticals Inc. $49,831.00 03/12/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A STUDY TO EVALUATE VIMSELTINIB IN ADULTS WITH ACTIVE CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) No dispute reported 06/30/2026 1235967558
Principal investigator 1 Syndax Pharmaceuticals, Inc. $57,254.96 03/10/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
AGAVE-201, A PHASE 2, OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF AXATILIMAB AT 3 DIFFERENT DOSES IN PATIENTS WITH RECURRENT OR REFRACTORY ACTIVE CHRONIC GRAFT VERSUS HOST DISEASE WHO HAVE RECEIVED AT LEAST 2 LINES OF SYSTEMIC THERAPY No dispute reported 06/30/2026 1249049454
Principal investigator 1 SANOFI US SERVICES INC. $7,754.31 03/04/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of Belumosudil in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease (cGVHD) No dispute reported 06/30/2026 1226084441
Principal investigator 1 SANOFI US SERVICES INC. $16,748.00 03/04/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of Belumosudil in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease (cGVHD) No dispute reported 06/30/2026 1226084449
Principal investigator 1 SANOFI US SERVICES INC. $11,105.00 02/24/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of Belumosudil in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease (cGVHD) No dispute reported 06/30/2026 1226084454
Principal investigator 1 Incyte Corporation $2,500.00 02/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470609
Principal investigator 1 Incyte Corporation $1,000.00 02/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470611
Principal investigator 1 Incyte Corporation $1,500.00 02/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470613
Principal investigator 1 Incyte Corporation $7,500.00 02/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470615
Principal investigator 1 Incyte Corporation $2,500.00 02/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470617
Principal investigator 1 Incyte Corporation $11,000.00 02/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470619
Principal investigator 1 Incyte Corporation $4,000.00 02/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470621
Principal investigator 1 Incyte Corporation $2,500.00 02/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240470623
Principal investigator 1 Deciphera Pharmaceuticals Inc. $435.00 02/20/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A STUDY TO EVALUATE VIMSELTINIB IN ADULTS WITH ACTIVE CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) No dispute reported 06/30/2026 1235967550
Principal investigator 1 Deciphera Pharmaceuticals Inc. $435.00 02/20/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A STUDY TO EVALUATE VIMSELTINIB IN ADULTS WITH ACTIVE CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) No dispute reported 06/30/2026 1235967554
Principal investigator 1 National Marrow Donor Program $717.00 02/07/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events (MEASURE) No dispute reported 06/30/2026 1249325751
Principal investigator 1 Deciphera Pharmaceuticals Inc. $290.00 02/05/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A STUDY TO EVALUATE VIMSELTINIB IN ADULTS WITH ACTIVE CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) No dispute reported 06/30/2026 1235967543
Principal investigator 1 Deciphera Pharmaceuticals Inc. $290.00 02/05/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A STUDY TO EVALUATE VIMSELTINIB IN ADULTS WITH ACTIVE CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) No dispute reported 06/30/2026 1235967546
Principal investigator 1 Deciphera Pharmaceuticals Inc. $40,000.00 01/17/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A STUDY TO EVALUATE VIMSELTINIB IN ADULTS WITH ACTIVE CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) No dispute reported 06/30/2026 1235967539
Principal investigator 1 SANOFI US SERVICES INC. $20,529.00 01/13/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of Belumosudil in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease (cGVHD) No dispute reported 06/30/2026 1226084489
Principal investigator 1 SANOFI US SERVICES INC. $3,027.00 01/13/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of Belumosudil in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease (cGVHD) No dispute reported 06/30/2026 1226084493
Principal investigator 1 SANOFI US SERVICES INC. $26,974.00 01/13/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of Belumosudil in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease (cGVHD) No dispute reported 06/30/2026 1226084498